# Evaluating the Impact of Oral Contraceptives on Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Analysis

**Authors:** Yuxin Tang, Yu Zhang, Shuaiyi Wang, Xinyi Shi, Xinjia Ruan, Yu Cheng, Fangrong Yan, Tiantian Liu

PMC · DOI: 10.3390/biomedicines13061351 · 2025-05-31

## TL;DR

This study uses genetic data to suggest that using oral contraceptives may increase the risk of pancreatic cancer, possibly through specific proteins.

## Contribution

The study provides genetic evidence of a potential causal link between oral contraceptive use and increased pancreatic cancer risk.

## Key findings

- Five drug-targeted proteins were significantly associated with pancreatic cancer risk.
- Higher levels of COMT, AGT, FN1, and UGT1A1 and lower levels of SERPINC1 were linked to increased PC risk.
- AGT, FN1, and COMT showed consistent associations across multiple analyses.

## Abstract

Background: The relationship between oral contraceptive (OC) use and pancreatic cancer (PC) risk remains controversial, with inconsistent findings reported in observational studies. To clarify this relationship and better identify potential risk factors for PC prevention, more unbiased and robust approaches are needed. Methods: We investigated the potential causal relationship between OC use and PC risk using a two-sample Mendelian randomization (MR) analysis, with blood protein quantitative trait loci (pQTLs) as instrumental variables. To ensure the robustness of our findings, we performed a series of sensitivity analyses, colocalization analyses, and reverse MR. The causal effects of protein-coding genes on PC risk, as well as their expression patterns across different single-cell types, were subsequently investigated. To elucidate the potential pathogenic pathways, we conducted pathway enrichment analysis, protein–protein interaction (PPI) network analysis, and causal inference. Results: Our MR analysis identified five drug-targeted proteins significantly associated with PC risk. Higher levels of COMT, AGT, FN1, and UGT1A1, as well as lower levels of SERPINC1, were associated with an increased risk of PC. Among these, AGT, FN1, and COMT demonstrated consistent associations across sensitivity analyses and downstream analyses, providing robust evidence supporting their involvement in PC risk. Conclusions: This study provides genetic evidence suggesting, in European groups, a potential causal link between OC use and increased PC risk, possibly mediated through drug-targeted proteins such as AGT and FN1. These results highlight the importance for further research to elucidate the underlying mechanisms and assess the implications of OC use on PC risk.

## Linked entities

- **Genes:** COMT (catechol-O-methyltransferase) [NCBI Gene 1312], AGT (angiotensinogen) [NCBI Gene 183], FN1 (fibronectin 1) [NCBI Gene 2335], UGT1A1 (UDP glucuronosyltransferase family 1 member A1) [NCBI Gene 54658], SERPINC1 (serpin family C member 1) [NCBI Gene 462]
- **Diseases:** pancreatic cancer (MONDO:0005192)

## Full-text entities

- **Genes:** FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, UGT1A1 (UDP glucuronosyltransferase family 1 member A1) [NCBI Gene 54658] {aka BILIQTL1, GNT1, HUG-BR1, UDPGT, UDPGT 1-1, UGT1}, AGT (angiotensinogen) [NCBI Gene 183] {aka ANHU, SERPINA8, hFLT1}, COMT (catechol-O-methyltransferase) [NCBI Gene 1312] {aka HEL-S-98n}, SERPINC1 (serpin family C member 1) [NCBI Gene 462] {aka AT3, AT3D, ATIII, ATIII-R2, ATIII-T1, ATIII-T2}
- **Diseases:** PC (MESH:D010190)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12190781/full.md

---
Source: https://tomesphere.com/paper/PMC12190781